RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
33,82 $US
arrow_upward
+10,22%(+3,13) 1J
30 juin, 12:04:02 UTC−4 · USD
search
Tous les symboles
1J
5J
1M
6M
Depuis début année
1AN
5ANS
MAX
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour RARE...
Ouverture
31,01 $US
Élevé
33,97 $US
Faible
30,48 $US
Cap. boursière
3,33 Md
Vol. moyen
2,39 M
Volume
2,19 M
+ haut sur 1 an
42,37 $US
+ bas sur 1 an
18,29 $US
BPA
-6,10 $US
Bêta
0,37
Actions en circulation
98,49 M
Nombre d'employés
1 k
Ouverture
31,01 $US
Élevé
33,97 $US
Faible
30,48 $US
Cap. boursière
3,33 Md
Vol. moyen
2,39 M
Volume
2,19 M
+ haut sur 1 an
42,37 $US
+ bas sur 1 an
18,29 $US
BPA
-6,10 $US
Bêta
0,37
Actions en circulation
98,49 M
Nombre d'employés
1 k
Articles
Provenant de diverses sources sur le Web
Investing News Network
·
il y a 28 minutes
NYSE Content Update: Klaviyo Launches AI Agents to Elevate Consumer Brands
Moomoo
·
il y a 58 minutes
Dow Jones Top Financial Services Headlines at 11 AM ET: America Needs More Weapons. JPMorgan Wants to Add Its Firepower. | Strategy ...
fr.qz.com
·
il y a 18 heures
Les contrats à terme sur actions augmentent alors que les États-Unis et l'Iran conviennent de stopper les dernières attaques.
Seeking Alpha
·
il y a 1 jour
US stocks advance on Middle East de-escalation, tech rebound (SP500:)
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
À propos de Ultragenyx Pharmaceutical Inc
PDGEmil Kakkis
Employés1,37 k
Date de création2010
Siège socialNovato, Californie, États-Unis
Secteur-
Site Webultragenyx.com
Les contenus générés par IA peuvent contenir des erreurs. En savoir plus